Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis
Chronic Respiratory Disease · 2023
DOI: 10.1177/14799731231210559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chronic Respiratory Disease, 2023. Verfasst von Fengjia Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Asthma, Bronchiectasis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, GuangDong Basic and Applied Basic Research Foundation, GuangDong Medical Science and Technology Research Foundation.
Abstract (Originalsprache)
Objective
Recently, a type 2 inflammation (T2) high endotype in bronchiectasis was identified. The fraction of exhaled nitric oxide (FeNO) and blood eosinophil count (BEC) are recognized as representative biomarkers of T2 inflammation. Herein, we investigate the clinical characteristics of T2-high endotype in non-cystic fibrosis bronchiectasis patients classified by FeNO and BEC.
Methods
This retrospective study included 164 bronchiectasis patients treated in the First Affiliated Hospital of Sun Yat-sen University from December 2017 to July 2022. Clinical characteristics were analyzed after classifying patients into four groups according to T2 inflammation biomarkers (FeNO ≥25 ppb; BEC ≥200/µL).
Results
Among the 164 bronchiectasis patients, 35.3% (58/164) presented with high FeNO, 30.5% (50/164) presented with high BEC, and 10.4% (17/164) had high FeNO and BEC. Patients with high FeNO and low BEC presented with better lung function, fewer affected lobes, and lower dyspnea prevalence compared with the three other groups. Moreover, decreased FeNO, instead of decreased BEC, is revealed to be an independent predictor for disease severity and airflow obstruction in bronchiectasis.
Conclusions
Simultaneous evaluation of FeNO and BEC proposed different endotypes of bronchiectasis established that patients with low BEC and high FeNO had better lung function, fewer affected lobes, lower dyspnea prevalence, and less disease severity. This result will contribute to a more comprehensive assessment of the disease severity and lead to more precise treatment of T2 inflammation in bronchiectasis patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Institute of Pulmonary Diseases, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Xinyan Huang, Yangli Liu
Förderung
- National Natural Science Foundation of China
- GuangDong Basic and Applied Basic Research Foundation
- GuangDong Medical Science and Technology Research Foundation
Zitieren
APA
Chen, F., Zeng, Z., Huang, X., & Liu, Y. (2023). Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis. Chronic Respiratory Disease. https://doi.org/10.1177/14799731231210559
Vancouver
Chen F, Zeng Z, Huang X, Liu Y. Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis. Chronic Respiratory Disease. 2023. doi:10.1177/14799731231210559
BibTeX
@article{Chen2023,
author = {Chen, Fengjia and Zeng, Zhimin and Huang, Xinyan and Liu, Yangli},
title = {Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis},
journal = {Chronic Respiratory Disease},
year = {2023},
doi = {10.1177/14799731231210559}
}
EUVIMED